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Li9Fraumeni# syndrome# (LFS)# is# an# autosomal# dominant# disease# caused# by#
germline#mutations#in#the#gene#TP53,#which#predispose#individuals#to#a#wide#range#
of#malignancies,#including#osteosarcoma#and#breast#cancer.#In#the#previous#study,#
our# group# developed# a# novel# disease# model# platform# by# reprograming# LFS#
patients'# fibroblasts# to# induced# pluripotent# stem# cells# (iPSCs),# and# further#
differentiate#these#iPSCs#into#mesenchymal#stem#cells#(MSCs)#then#to#osteoblasts#











LFS# OBs# derived# tumors# were# identified,# including#USP34,# ANAPC1,# ESPL1,#
 vii#
MYLK,#SLC35G2,#FAM160A2,#SLC25A32,#SYNE2,#RPL8,#and#FAM20A.#These#
genes# are# potential# candidate# driver# genes# during# early# osteosarcoma#
development.#
Breast# cancer# is# the# most# common# tumor# among# women# with# germline# TP53#
mutations.# In# this#study,#we#also#generated# iPSC# lines# from#LFS#breast#cancer#




a# chemical# based# protocol.# Further# establishment# of# mammary# organoids#
differentiation#protocol#will# provide# in' vitro# platform# in#modeling#LFS#associated#
breast#cancer.#
In# addition,# we# successfully# corrected# TP53# mutation# (Y205C)# in# LFS# patient#
derived#iPSCs#using#TALEN9mediated#precise#gene#editing.#Similar#approach#was#
used# to# generate# two# H1# human# embryonic# stem# cells# (hESCs)# carrying#
homozygous# TP53' R282W# and# TP53# R248W# mutation.# These# engineered#
iPSCs/hESCs#offers#exciting#opportunities#for#studying#mechanisms#of#mutant#p53#

































































































































































Figure# 41.# Correction# of# mutant# p53# (Y205C)# iPSC# using# TALENs9mediated#
precise#gene#editing.#.........................................................................................#141#
Figure# 42.# Correction# of# mutant# p53# (Y205C)# iPSC# using# TALENs9mediated#
precise#gene#editing#(continued).#......................................................................#142#

















































Li9Fraumeni# Syndrome# (LFS)# [Online# Mendelian# Inheritance# in# Man# (OMIM)#
151623]#https://www.omim.org/entry/151623]#is#a#rare#familial#autosomal#dominant#
cancer#syndrome#characterized#by#early#onset#of#multiple#tumors,#particularly#soft9
tissue# sarcomas,# osteosarcomas,# breast# cancers,# brain# tumors,# adrenocortical#
carcinomas,#and#leukemia.#LFS#was#first#described#in#1969#by#Li#and#Fraumeni#(1,#
2)#(Figure)1).#In#reviewing#280#medical#charts#and#418#death#certificates#of#648#
childhood# rhabdomyosarcoma# patients# in# the# USA# from# 1960# to# 1964,# they#
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or# a# sarcoma# at# any# age.# This# definition# was# based# on# 24# kindreds# with# the#
syndrome#of#sarcoma,#breast#carcinoma,#and#other#neoplasms#in#young#patients#
(3).#The#defined#criteria# for# this#syndrome#gradually#evolved# to# include#not#only#
classic#LFS#but#also#LFS9like#syndrome#(LFL),#which#shares#features#of#LFS#but#
does#not#conform#to#the#strict#definition#(4).#













related# secondary# malignancies.# Several# case# reports# suggested# that# ionizing#
radiation9induced#cancers#are#more#common#in#LFS#patients#(11913),#and#research#
studies# also# support# this# relationship# (14,# 15).# Therefore,# radiation# therapy# is#
generally# avoided# in# the#management# of# these# patients# if# possible.# A# stringent#
surveillance#strategy#is#one#of#the#key#components#of#LFS#patient#management.#A#
prospective# clinical# trial# aimed# at# improving# cancer# screening# for# LFS# patients#




mutation# to#LFS#(17).#Srivastava#et'al.# later#analyzed#TP53'mutations# in#a#LFS#
family,# identifying# the# same# point# mutation# in# codon# 245# of# the#TP53# gene# in#
different#generations#of#this#pedigree#(18).#Together#with#the#previous#observations#
that#p53#is#also#inactivated#in#the#sporadic#(nonfamilial)#forms#of#cancers,#these#




families# (17).# Numerous# subsequent# studies# have# shown# that# ~70%# of# LFS#
families#harbor#detectable#germline#TP53#mutations#(4,#19922).#These#mutations#
are# also# highly# associated# with# a# significant# increase# in# DNA# copy9number#
variations#(CNVs)#(23).#For#those#patients#without#detectable#TP53#mutations,#a#
complete#heterozygous#germline#deletion#of#TP53#was# reported# (24),# indicating#
 4#
that#rearrangements#affecting#TP53#occur#rarely,#but#should#be#considered#in#LFS#
families.# According# to# the# National# Comprehensive# Cancer# Network# (NCCN)#




700# LFS# pedigrees# have# been# reported# and# integrated# into# the# International#






much# broader# role# in# many# normal# cellular# and# developmental# processes# in#
addition#to#its#well9known#tumor9suppressor#function.#The#most#extensively#studied#
mechanism# by#which#wild9type# (WT)# p53# functions# is# as# a# transcription# factor,#
regulating# the# expression# of# a# set# of# target# genes# involved# in# cell9cycle# arrest,#
senescence,#apoptosis,#and#DNA#damage# repair# (27929).#Beyond# these#classic#
functions,# p53# also# plays# roles# in# regulating# glucose# metabolism# (30,# 31),#
antioxidant# activity# (31933),# autophagy# (34,# 35),# motility# and# invasion# (36),#
angiogenesis# (37),# bone# remodeling# (38,# 39),# stem# cell# self9renewal# (40,# 41),#




of# p53# in# which# WT# function# can# prevent# cell# death# or# even# promote# cancer#
development#and#progression#(53955).#






gain9of9function,# inconsistent# findings# from# different# study# systems,# and# the#






discovery# of# the# disease,# identification# of# the# underlying# genetic# cause,# and#
establishment#of#a#disease#model.#The#right#column#timeline#lists#the#equivalent#






truncation# mutations# in# p53# abrogate# its# normal# function# by# attenuating# p539
responsive#cellular#activities]#when#both#alleles#become#mutated,#the#anticancer#
protection#of#p53#is#shut#down.#Although#p53#loss#of#function#is#a#common#feature#
of#cancer,#p53#does#not# fully# follow# the#classic#Knudson’s# two9hit# theory#during#
carcinogenesis#or#cancer#progression#(62).#It#is#not#simply#the#loss#of#WT#p53#that#
drives# cells# to# cancer.# The#majority# of# the# p53#mutations# found# in# tumors# are#
missense#mutations,#resulting#in#production#of#full9length#protein#with#only#a#single#
amino# acid# change# (63).# Many# of# these# mutant# proteins# exhibit# a# mutant# p53#
dominant#negative#effect#over#WT#p53,#mostly#by# forming#mixed# tetramers#with#
diminished#DNA9binding#and#transactivation#activity#(64).#In#this#way,#mutation#of#
only# one# copy# of# p53# can# lead# to#many# of# the# downstream# effects# that# would#
otherwise#require#loss#of#both#copies.#
Probably#the#most#striking#fact#about#the#p53#mutation#landscape#in#cancer#is#the#
high# prevalence# of#missense# substitutions# at# particular# locations,#mainly# in# the#








99),#and# tumor# related# inflammation#(1009103).#Mutant#p53#gain9of9function#can#
drive# cancer# through# several# potential# mechanisms# (104,# 105):# (i)# binding# to#
structure9specific# DNA# to# subsequently# exert# transcriptional# regulation,# (ii)#
interacting# with# transcription# factors# or# cofactors# to# enhance# or# decrease# the#
transcription# of# their# targeted# genes,# (iii)# associating# with# chromatin# or# the#









TP53# missense# mutation# data# are# obtained# from# the# International# Agency# for#
Research#on#Cancer#(IARC)#TP53#database#(http://p53.iarc.fr/).#The#distribution#of#
p53#mutations# is# plotted# over# the# function# of# amino# acid# position]# the# left# side#
indicates#germline#mutations#and#the#right#side#indicates#somatic#mutations.#The#
horizontal#axis#shows#the#frequency#of#any#mutation#at#the#indicated#residues.#The#
vertical#axis# represents#p53#protein#starting#with# the#N9terminus#at# the# top.#p53#
protein#contains#transcriptional#activation#domains#I#and#II#(TAD#1,#20–40]#TAD#II,#
40–60),#the#proline#domain#(PP,#60–90),#the#sequence9specific#core#DNA9binding#
domain# (DNA9binding#core,#DBD]# residues#100–300),# the# linker# region# (L,#301–
324),# the# tetramerization# domain# (Tet,# 325–356),# and# the# lysine9rich# basic# C9
terminal# domain# (++,# 363–393).# The# most# common# mutations# or# hotspots# are#




the#most#commonly#seen# for# the# five#hotspot#germline#mutations]#malignancies#













to#be#negatively# regulated#by#p53# (120).# In#2015,# this# link#was#extended# to# the#
mutant#p53.#A#study#by#Lee#et'al.#revealed#that#numerous#p53#mutants#exhibit#gain#
of# function# and# can# inhibit# H19# expression# (122).# Using# LFS# patient9derived#
induced#pluripotent#stem#cells#(iPSCs)#to#model#osteosarcoma,#this#study#found#
that# the# p53# (G245D)# mutant# represses# H19# expression# during# osteoblastic#
differentiation.#Moreover,#many# hotspot# p53#mutants# including#R175H,#G245S,#
R248W,#and#R280K#also#showed#strong#inhibition#of#H19#expression#compared#to#
WT#p53,#indicating#that#mutant#p53#gain9of9function#in#regulating#imprinted#gene#




chromatin# and# other# transcriptional# factors# to# globally# influence# the# gene#
 11#
expression#profile# (76,#96,#101,#123,#124).#Recently,# it#was#shown# that#multiple#
mutant#p53#forms#bind#to#the#SWI/SNF#chromatin#remodeling#complex#(92).#This#
interaction# with# the# SWI/SNF# complex#mediates# up# to# 40%# of# the#mutant# p53#









MLL2,# and# KAT6A,# resulting# in# a# global# increase# of# histone# modifications#











region.#The# study#also# showed# that# inhibition#of#PDGFRB#using#RNAi# or# small#















in' vitro# studies# of# LFS.# In# 1992,# to# investigate# the# role# of# the# Tp53# gene# in#
mammalian#development#and#tumorigenesis,#a#null#mutation#was#introduced#into#
the# gene# by# homologous# recombination# in#murine# embryonic# stem# cells# (130).#
Mice#homologous#for#the#null#allele#(Tp53I/I)#appear#to#be#developmentally#normal#
but#are#highly#susceptible#to#early#onset#of#a#variety#of#neoplasms.#Subsequent#





were# generated.#Nearly# 50%#of# them# developed# tumors# by# 18#months# of# age,#
although#with# a# comparative# cancer# onset# delay# compared# to# the# homozygous#
mice.# This# was# roughly# similar# to# the# 50%# cancer# incidence# before# age# 30# in#
affected#LFS#individuals,#given#that#C57BL/6#mice#have#an#average#lifespan#of#30#
to#36#months#(133).#The#similarities#between#Tp53+/I#mice#and#LFS#patients#are#
even#more# striking# with# respect# to# their# tumor# spectrum.#Tp53+/I# mice# develop#
osteosarcomas# and# soft# tissue# sarcomas,# as# seen#with# high# frequency# in# LFS#





attention# in# the#p53#research#community.# In#2000# the# first#heterozygous#mouse#
containing#an#R# to#H#substitution#at#p53#amino#acid#172#was#generated,#which#
corresponds#to#the#R175H#hotspot#mutation#in#human#cancers#and#the#germline#















human# LFS# familial# syndrome# than# do#Tp53+/I# mice.# Interestingly,#Tp53M/I# and#
Tp53+/I#mice#did#not#develop#breast#cancer,#one#of# the#most#common#tumors# in#
LFS# patients,# but# increased# the# incidence# of# hematological#malignancies# (e.g.,#
 16#
lymphomas)# (136,# 137),# implying# that# either# species# differences# or# a# specific#
susceptible# genetic# background# influence# the# ability# of# these#model# models# to#
recapitulate#human#LFS.##
Similarly,#HUPKI#mouse#models#(humanized#TP53#knock9in#models)#(138)#were#
constructed# by# targeting# the# mutant# human# TP53# DNA# sequence# into# murine#
embryonic# stem#cells# (Table)1).#HUPKI#models#were#generated# for# the#human#
mutations#R175H,#G245S,#R248W,#R248Q,#and#R273H#(65,#139,#140).#All#these#
knock9in#mice#except#the#G245S#model#showed#a#broader#tumor#spectrum#than#
Tp53# null# mice,# providing# strong# support# for# the# gain9of9function# hypothesis# of#






ionizing# radiation# (IR)9induced# phenotype# in# zebrafish# embryos,# leading# to# the#
identification#of#the#p53#I166T#mutations.#This#mutation#was#shown#to#give#rise#to#
tumors,# predominately# sarcomas,# with# 100%# penetrance# in# adult# fish.# As# in#
humans#with#LFS,#heterozygous#tp53I166T#fish#follow#Knudson’s#two9hit#hypothesis,#
and# the# tumors# displayed# loss# of# heterozygosity# (LOH)# at# the# tp53# locus.#
Additionally,# the# data# demonstrated# that# the# p53# regulatory# pathway,# including#





Researchers# have# also# gained# insight# into# LFS# through# direct# investigation# of#
patient# primary# cells.# A# comparison# of# soft# tissue# sarcomas,# including#
fibrosarcomas,# from# affected# LFS# patients# with# fibroblasts# derived# from# skin#




and# telomere#elongation# (1449146).#Loss#of#p53#during# this# immortalization#has#
been# shown# to# cause# a# decrease# in# TSP91# expression,# a# potent# inhibitor# of#
angiogenesis,#and#switch#the#LFS#fibroblasts#to#a#pro9angiogenic#phenotype#(147,#
148).#In#addition,#normal#breast#epithelial#cells#obtained#from#a#patient#with#LFS#









To# access# a#wider# spectrum# of# cell# types,# iPSCs#were# generated# from# patient#
fibroblasts#obtained#from#a#LFS#family#with#a#heterozygous#TP53'(G245D)#hotspot#
mutation#and#differentiated# into# targeted# lineages# (122)# (Table)1).#Despite# their#
defective# p53# function,# LFS# iPSC9derived# mesenchymal# stem# cells# (MSCs)#
maintained# normal# MSC# characteristics# and# could# be# differentiated# into#
osteoblasts.# Interestingly,# once# turned# into# osteoblasts,# genome9wide#





the# cytogenetic# rearrangements# that# are# commonly# found# in# osteosarcoma,#
indicating#the#existence#of#a#relatively#intact#genome#in#this#model#system#and#the#
feasibility#of#studying#early#cancer#progression#before#the#accumulation#of#broad#
genome# alterations.# These# data# show# that# the# LFS# iPSC# disease# model#























Zebrafish# I166T# Dominant#negative# Yes#
Broad#



































In# 1998,# Thomson# and# colleagues# isolated# human# ESCs# (see# Glossary)# from#
blastocysts#and#developed#a#defined#culture#system#to#maintain#the#cells#in'vitro#
(152),# opening# a# new# avenue# for# medical# research.# Later,# in# 2006–2007,# a#






subsequent# advances# facilitated# the# generation# of# iPSCs# with# chemicals,#
microRNA# and# modified# RNA,# or# other# gene# delivery# systems# (retroviruses,#
 20#
adenoviruses,#Sendai# virus,# transposons,# and# plasmids)# (154).# Applications# for#
iPSCs# include# regenerative# medicine,# disease# modeling,# drug# screening,# and#
personalized#therapy.#
The# unique# combination# of# pluripotency# and# self9renewal# distinguishes# PSCs,#
including#both#ESCs#and# iPSCs,# from#all#other#cells.#The#unlimited#proliferative#
potential# of# these# undifferentiated# cells# provides# an# arbitrarily# large# source# of#
experimental# material,# while# their# pluripotency# allows# them# to# be# coaxed# into#
forming# all# adult# tissue# types.# Well9defined# protocols,# including# directed#
differentiation#and#organoid#cultures#have#been#developed#to#derive#many#major#
target# tissues# and# cell# types# from# PSCs# of# endodermal# (liver,# small# intestine,#




progenitor# into# a# differentiated# cell# type# of# interest.# The# relevant# genetic#
background#for#the#model#system#can#be#introduced#into#PSCs#using#two#primary#
strategies.#In#one#approach,#somatic#cells#from#patients#with#genetic#disorders#are#







PSC9derived# cell# lines# have# been# generated# to#model# disorders# with# a# cancer#








and# small# organism#models# (e.g.,# fruit# fly,# zebrafish,# and#mouse)# to# study# the#
molecular#mechanisms#of#cancer#initiation,#progression,#and#metastasis,#but#the#
complexity#of#the#cancer#genome#and#differences#among#species#frequently#limit#




Li–Fraumeni# syndrome# (LFS)# is# an# autosomal# dominant# inherited# cancer#
syndrome#that#is#characterized#by#early#onset#of#a#variety#of#tumor#types,#including#
soft9tissue# sarcoma# and# osteosarcoma,# breast# cancer,# brain# tumors,# leukemia,#
and#adrenocortical#carcinoma#(3).#Our#group#established#a#model#of#LFS#using#
patient9derived# iPSCs# to#delineate#mechanisms#of#mutant#p53# in#osteosarcoma#
 22#
(122).# In# this# system,# osteoblasts# differentiated# from# LFS# iPSC# derived#




cytogenetic# rearrangements,# permitting# study# of# early# oncogenic# mechanisms#
prior# to#accumulation#of# secondary#genomic#alterations.#Expression#of# the# long#
noncoding# RNA# H19# had# been# previously# linked# to# p53# activity# (120)# and#
transcriptome#analysis#suggested#impaired#expression#of#H19#in#LFS#osteoblasts.#
Further#functional#studies#showed#that#H19#is#essential#for#normal#osteogenesis#
and# inhibition# of# tumorigenesis.# The# LFS# iPSC# disease# model# uncovered# a#
previously# unidentified# role# of# p53# in# osteogenic# differentiation# defects# and#
tumorigenesis.#
Noonan)syndrome)
Noonan# syndrome# (NS)# is# an# autosomal# dominant# disorder# characterized# by# a#
wide#spectrum#of#congenital#heart#abnormalities,#short#stature,#facial#dimorphism,#
and# predisposition# to# hematological#malignancies.# A# subset# of#NS# patients#will#
develop# juvenile# myelomonocytic# leukemia# (JMML),# an# aggressive#
myelodysplastic# and# myeloproliferative# neoplasm# (172).# Mulero9Navarro# et' al.#
(168)# investigated# the#molecular#mechanisms# involved# in#NS9associated# JMML#
harboring#PTPN11#mutations# using# hematopoietic# cells# derived# from#NS/JMML#
patient9specific# iPSCs.# These# hematopoietic# cells# recapitulated# several# JMML#
characteristics# including# hypersensitivity# to# granulocyte9macrophage# colony9
 23#
stimulating#factor#and#increased#myeloid#population.#Comparison#of#transcriptome#
profiles# of# controls# and# NS/JMML9derived# CD33+# myeloid# cells# confirmed#










hematopoiesis# and# a# disposition# to# develop# anemia,# cytopenia,# and# leukemia.#
Sporadic# loss# of# one# copy# of# the# long# arm# of# chromosome# 5# [del(5q)]# and/or#
chromosome#7#[del(7q)]#is#a#characteristic#cytogenetic#abnormality#in#MDS#(173).#
Kotini#et#al.#(169)#established#del(7q)#MDS#iPSCs#from#patient#hematopoietic#stem#
cells# with# loss# of# chromosome# 7q# and# iPSCs# derived# from# normal# fibroblast#
isogenic# controls.# iPSCs# with# del(7q)# recapitulated# the# phenotype# of# impaired#
myeloid#lineage#differentiation#seen#in#MDS.#This#defective#differentiation#potential#
could# be# reproduced# by# engineering# hemizygosity# of# definite# 7q# segments# in#
normal# iPSCs# and# could# be# rescued# by# spontaneous# acquisition# of# an# extra#
chromosome#7.#Through#phenotype9rescue#screening,#Kotini#et'al.#(169)#identified#
 24#










PDGFRA# (D842V)# and# p53# small# hairpin#RNA.# In# this#NPC#model,# H3.3K27M#
expression# synergized# with# PDGFRA# activation# and# p53# loss,# culminating# in#
neoplastic# transformation.# Genome9wide# analyses# of# H3.3K27M9transformed#
NPCs#revealed# that# they#maintain#both#an#undifferentiated#epigenome#structure#









diverse,#mutations# in#PTEN#are#common#and#correlate#with# increased# invasion,#
drug#resistance,#and#tumor#recurrence#(176).#Duan#et'al.#(171)#engineered#PTEN9
deficient#ESCs#using#a#TALEN9based#genome#editing#methodology#and#derived#
neural# stem# cells# (NSCs)# to# model# GBM.# PTEN9deficient# NSCs# displayed# the#
GBM9associated#gene#signature#and#formed#intracranial#tumors#in#vivo.#Duan#et#
al.# (171)# found# that# elevated# levels# of# PAX7# contributed# to# neoplastic#


































































































Advances# in#genomics#have# led# to#an#exponential# increase# in#available#cancer#
genomic#data#and#finally#directed#us#to#the#gene#mutations#that#drive#cancer.#In#
some#cases,#mutations# found# in#only#a# fraction#of# cells#extracted# from#a#single#
patient#tumor#sample#can#be#identified.#Nevertheless,#translation#of#this#knowledge#
into#personalized#therapy#is#far#from#reality.#One#of#the#biggest#bottlenecks#is#how#
to# convert# knowledge# of# a# specific# genomic# alteration# into# a# therapeutic# assay#
against#which#therapies#can#be#targeted#(177).#Hundreds#of#TP53#mutations#have#






























dominant# negative# mutations# (181)# into# WT# PSCs# recapitulates# the# long9QT#



















culture# medium# (Table) 3).# Fibroblast# reprogramming# were# performed# by#
transducing#Sendai#virus#expressing#the#four#reprogramming#factors#OCT4,#SOX2,#
KLF4,# and# c9MYC# (CytoTune# iPS# 2.0# Sendai# Reprogramming# Kit,# Invitrogen)#





2.2) iPSC/hESC) culture) in) feeder) culture) condition) (on) mouse) embryonic)
fibroblast))
iPSCs,# hESCs# and# the# engineered# clones#were# cultured# on#mouse# embryonic#
fibroblasts# (MEFs)# in# hESC# medium# (Table) 3)# and# maintained# at# 37# °C# in# a#
humidified# 5%# CO2# incubator.# Cells# were# passaged# using# Accutase# cell#
 30#
detachment#solution#(Corning)#when#reaching#85%#confluence.#Mouse#embryonic#
fibroblast# (MEF)# culture# dishes# were# prepared# one# day# before# cell# passaging.#
Tissue#culture#dishes#were#coated#with#0.1%#gelatin#at#room#temperature#for#30#
min.# The# gelatin# was# aspirated# after# coating.# 6.7# ×# 105# irradiated# CF1# MEFs#
(Thermo#Fisher)#were#seeded#per#100#mm#dish#using#MEF#culture#medium#hESC#
medium#with#2#μM#ROCK#inhibitor#Thiazovivin#(Calbiochem)#to#improve#survival#of#





coated# plates# in# StemMACS™# iPS9Brew# XF# medium# (Miltenyi# Biotec)# and#
maintained#at#37#°C#in#a#humidified#5%#CO2#incubator.#Cells#were#passaged#using#
StemMACS™# Passaging# Solution# XF# (Miltenyi# Biotec)# when# reaching# 85%#
confluence.#The#plates#were#pre9coated#with#basement#membrane#matrix#coating#
solution#(Table)3)#for#1#hour#at#room#temperature.#hESC#medium#with#2#μM#ROCK#












































































Cells#were# fixed#with# 4%#paraformaldehyde# for# 15miutes# at# room# temperature,#
blocked# with# 10%# serum# in# Dulbecco's# phosphate9buffered# saline# (DPBS)#
supplemented#with#0.01%#Tween920#(Sigma)#(DPBST)#at#room#temperature#for#1#
hour.#After#blocking,# cells#were# incubated#with# the# indicated#primary#antibodies#
(Table)4)#at#4#°C#overnight.#Cells#were#then#washed#with#DPBST#3#times#at#room#
temperature,# and# incubated# with# corresponding# secondary# antibodies# at# room#
temperature#for#1#hour.#DAPI#counterstaining#was#performed#by#incubating#cells#
with# 3# μM# DAPI# (Thermo# Fisher)# diluted# in# DPBS# at# room# temperature# for# 5#
minutes.#The#results#were#visualized#by#Leica#DMi8.#
Antibody)Name) Vender) Catalog)#) Dilution)
NANOG# R&D#System# AF1997# 1:500#
OCT4# Santa#Cruz# sc99081# 1:300#
SSEA94#PE9conjugated# R&D#System# FAB1435P# 1:600#







CD105# eBioscience# 1291057942# 1:500#
CD44# DB#Biosciences# 555478# 1:500#
CD73# DB#Biosciences# 550257# 1:500#
CD166# DB#Biosciences# 560903# 1:500#
CD24# DB#Biosciences# 555427# 1:500#
AP92α#(3B5)# Santa#Cruz# sc912726# 1:500#
AP2#gamma## Abcam# ab76007# 1:500#
Cytokeratin#18# Abcam# ab133263# 1:500#










Step) Temperature) Time) Cycle)
Denaturation# 95#°C# 30#seconds# #
Annealing# 55#°C# 30#seconds# 35#























Total#mRNA#was# isolated#using#TRIzol# (Invitrogen)# following#the#manufacturer's#
instruction.# 1# μg#of#RNA#was#used# for# cDNA#synthesis# using# the# iScript# cDNA#
































iPSC,# hESCs# and# the# generated# clones# of# 65%# confluency# were# treated# with#
KaryoMAX#Colcemid#Solution#(Gibco)#for#3#hours.#Cell#pellets#were#then#carefully#
resuspended# in# hypotonic# KCI# solution# (7.5# mM)# for# 8# minutes# and# fixed# in#
Carnoy's#fixative#(3:1#methanol#to#glacial#acetic#acid).#The#G9banding#karyotype#
was#performed# in#Department#of#Pediatrics,#Baylor#College#of#Medicine,#Texas#











Mycoplasma# detection# was# performed# using# PCR# Mycoplasma# Detection# Kit#
(Applied#Biological#Materials#Inc)#according#to#the#manufacturer's#protocol.#
2.11)Short)tandem)repeat)(STR))analysis)
STR# analysis# was# performed# by# Characterized# Cell# Line# Core# Facility# at# The#
University#of#Texas#M.D.#Anderson#Cancer#Center.#The#number#of#STRs#at#14#loci,#
 37#
namely# AMEL,# CSF1PO,# D13S317,# D16S539,# D18S51,# D21S11,# D3S1358,#
D5S818,#D7S820,#D8S1179,#FGA,#TH01,#TPOX#and#vWA#were#assessed.#
2.12)Differentiation)of)iPSCs)to)mesenchymal)stem)cells)(MSCs))
iPSC# clones# were# mainlined# in# feeder# culture# condition# for# at# least# 2# weeks.#
Cultured#iPSCs#in#100#mm#tissue#culture#dishes#with#80#9#90%#confluence#were#
dissociated# with# Accutase# cell# detachment# solution# (Corning).# MEF# culture#
medium#were#added#to#neutralize#the#detachment#solution#and#transfer#cells#in#a#
new#100#mm#dish.#Incubate#the#cells#at#room#temperature#for#30#min#to#allow#the#
MEFs# to# attach# to# the# plate.# After# MEF# removal,# iPSCs# were# seed# with# MSC#




0.1%# gelatin9coated# plate# for# MSC# maturation# (Day# 28945).# When# the# MSCs#
display#a#fibroblast9like#morphology,#immunofluorescent#staining#of#MSC#surface#
markers#CD44,#CD73,#CD105,#and#CD166#were#performed#to#confirm#success#of#


































then# passed# through# 40# μm# cell# strainer# to# remove# aggregated# cells# and#
 39#
resuspended# in#osteoblast#differentiation#medium#(ODM)#with#0.5%# low#melting#
point#agarose# (Lonza).#The#cell#suspensions#were# then#plated# in#129well#plates#
containing#solidified#1%#agarose#in#ODM.#Control#experiments#were#performed#in#
parallel#with#MSCs# in# the#same#manner:# cells#were#maintained# in#MSC#culture#












solution# (Table) 3)# and# pass# the# cells# through# a# 70# μm# cell# strainer# to# remove#
aggregated#cells.##
For#subcutaneous#injection,#resuspend#the#1#x#107#osteoblasts#in#50#μL#ice9cold#1x#






















Resuspend# the# tumor# pieces# in# 1# x# DPBS# and# transfer# into# a# 15mL# tube# and#










using# REAL# Assembly# TALEN# kit# (Addgene)# and# inserted# into# JDS# vectors#
according#to#protocol#(183).#
The#CRISPR/Cas9#guided#RNA#(double#nickase#design)#targeting#different#region#
of# TP53# were# designed# using# Guide# Design# Resources# (https://zlab.bio/guide9
design9resources).# CRISPR/Cas9# guides# targeting# sites# used# in# study# were#
 42#
summarized#Table)8.#The#designed#guides#were#then#constructed#into#pX3359U69








on# left# homologous.# Homologous# arms# were# then# digested# with# EcoRI# (left#
homologous#arm)#and#BamHI#and#NotI#(right#homologous#arm),#respectively,#and#
ligated# into# the# pFNF# (Frt9EM79NeoR9Frt)# vector.# To# generate# R282W# mutant#
donor# arm,# site9directed# mutagenesis# was# performed# on# right# homologous.#
Homologous#arms#were#then#digested#with#SalI#and#EcoRI#(left#homologous#arm)#
and#BamHI#and#NotI# (right# homologous#arm),# respectively,# and# ligated# into# the#











































































































































H1#hESC#genomic#DNA#were# isolated# by# the#PureLink#Genomic#DNA#Mini#Kit#
(Thermo#Fisher).#PCR#amplicons#including#nuclease#(TALENs#or#CRIPSR/Cas9#
guides)# target# sites# were# generated# using# the# forward# primer:# 5’9
CGCTTCGAGATGTTCCGAGA93’# and# reverse# primer:# 5’9 




2.20) Generation) of) engineered) iPSC) and) hESC) line) by) precise) genome)
editing)






hESC#medium# (Table) 1)# supplemented#with# 2# μM#ROCK# inhibitor# Thiazovivin.#
Cells# were# then# selected#with# 50# μg/ml#G418# for# 293#weeks# and#medium#was#































ice# for# 30#minutes#and#sonicated# for# 5# seconds#at# 20%# intensity# for# 598# times.#
Generally,#15930#μg#protein#lysate#were#resolved#by#various#percentages#of#SDS9




(Table) 11).# Subsequently#membranes#were#washed# three# times# by# TBST# and#
incubated#with#secondary#antibodies#for#1#hour#at#room#temperature#and#washed#
3# times#with# TBST.# Immunodetected# bands# on# the#membranes#were# recorded#
using#film#developer#in#darkroom#after#incubating#with#chemiluminescence#(ECL)#
system#(Roche#Molecular#Biochemicals).#
Antibody)Name) Vender) Catalog)#) Dilution)
p53# Santa#Cruz# sc9126# 1:1000#
AP2#gamma## Abcam# ab76007# 1:1000#















manufacturer's# protocol# (Roche# PCR#DIG# Probe# Systhesis# Kit,# 11636090910).#
Crosslinked# membrane# was# hybridized# and# washed# as# the# manufacturer#
recommended# (Roche# DIG# Easy# Hyb,# 11796895001).# Hybridized# membranes#
were# subsequently# treated# with# an# anti9DIG# antibody# and# bands# on# the#
membranes#were#recorded#using#film#developer#in#darkroom#after#incubating#with#
chemiluminescent# substrate# CDP9Star' (Roche# CDP9Star,# ready9to9use,#
12041677001).#
2.23) Culture) of) embryoid) bodies) (EB)) and) MammoCult/derived) embryoid)
bodies)(mEBs))
hESCs#(RUES2)#and#iPSCs#were#maintained#in#feeder9free#system#as#described#
in# Chapter# 2.3# with# growth# factor9reduced# BD# Matrigel# matrix# and# cultured# in#
chemically9defined#mTeSR1#medium#(StemCell#Technologies)#for#at#least#2#weeks#
before#EB#or#mEB# formation.#For#EB#culture,#hESCs#and# iPSCs#were# lifted#by#
Accutase#cell#detachment#solution#(Corning)#and#suspended#in#EB#medium#(Table)
3)]#for#mEB#culture,#the#lifted#hESCs#and#iPSCs#were#suspended#in#mEB#medium#
(Table) 3).# Embryoid# bodies# were# subsequently# formed# and# cultured# using#








(698# passages)# before# differentiation.# Cells# were# passaged# using# EDTA#
dissociation#solution#(Table)3))when#reaching#80%#confluence.#The#plates#were#






iPSCs# and# hESCs# with# 80%# confluent# were# detached# using# Accutase# cell#















domed9shape,# mixed# Matrigel# (2.5# mg/mL)/Collagen# I# (1# mg/mL)# gel# on# the#
Nunclon#delta#surface#culture#plate#(Sigma)#(Figure)5).#Mixed#gel#was#composed#
of#3#portions#of#10.1#mg/ml#Matrigel#and#1#portion#of#4#mg/mL#Collagen#I#(Advanced#

















instruction.#Quality# control,# library# construction,#exome#capture#and#sequencing#
was#performed#at#Novogene#Corporation.#






1809280# base# pairs# (bp)# using# hydrodynamic# shearing# system# (Covaris,#
Massachusetts,#USA).#Remaining#overhangs#were#converted#into#blunt#ends#via#
exonuclease/polymerase#activities#and#enzymes#were#removed.#After#adenylation#













indels# identified# in# dbSNPv137#and# the# 1000#Genomes#Project#was#performed#
using#Indel#Realigner#(GATK#v.3.390).#3#base#quality#was#recalibrated#with#GATK#
Base# Recalibrator# (GATK# v.3.390)# to# generate# analysis9ready# reads.# Somatic#
variant# calls# were# carried# out# using#MuTect# 2,# comparing# sequencing# data# by#
pairing#MSCs#with#OBs#and#tumor#derived#cells#respectively#(Figure)21A).#MuTect#
2# was# run# with# default# parameters# to# generate# analysis9ready# variant,# and#
functional#annotation#of#somatic#variant#were#carried#out#using#ANNOVAR#(184).#
Network2Canvas,)mutational)signature)analyses)and)Venn)diagram)
Pathway# analysis# and# mutational# signature# analysis# were# performed# using#
Network2Canvas# (http://www.maayanlab.net/N2C/)# (185)# and# web9based#
application# MusiCa# (http://bioinfo.ciberehd.org/GPtoCRC/en/tools.html)# (186).#














Recent# advance# in#methodologies# have#made# the#modeling# of# human# genetic#
diseases#with#patient#derived#induce#pluripotent#stem#cells#(iPSCs)#feasible#(122,#
169,# 1879190).# Taking# advantage# of# LFS# patient# iPSCs,# our# group# have#
successfully# delineated# the# fundamental# pathological# mechanism# caused# by#
mutant#p53#in#osteosarcoma#(122)#(Figure)6).#This#novel#disease#model#platform#
is#established#by#differentiating#LFS#iPSCs#into#MSCs#then#to#osteoblasts#(OBs),#
















osteosarcoma# gene# signatures# and# recapitulate# oncogenic# properties# of#
osteosarcoma.# This# novel# disease#model# platform# can# be# used# for# therapeutic#






accumulate# during# the# LFS# iPSC9derived# MSCs# to# osteoblasts# differentiation#
process# and# contribute# to# the# LFS9associated# osteosarcoma# development.# By#
differentiating# LFS# patient# derived# iPSCs# to# MSCs# then# to# osteoblasts,# it# is#
hypothesized#that#LFS#derived#osteoblasts#(sample#B)#will#start#to#gain#tumorigenic#
ability#(Figure)7).#Xenograft#tumor#model#can#be#established#from#subcutaneous#
injection# of# LFS# derived# osteoblasts# into# immunocompromised# mice.# LFS#
osteoblast# derived# in' vivo# tumor# (sample#C)#will# acquire# increased# tumorigenic#
ability,#and#serial#transplantation#of#the#first9round#tumor#enable#collection#of#tumor#
samples# (sample# D)# with# aggregating# tumorigenic# ability.# LFS# samples# with#
different# tumorigenic# potentials,# including# MSCs# (no# tumorigenic# ability),#
osteoblasts# (gaining# tumorigenic# ability),# and# osteosarcoma# grown# in#
subcutaneous# transplantation# (retaining# in' vivo# tumorigenic# ability),# and#
osteosarcoma# grown# in# serial# transplantation# (aggregating# in' vivo# tumorigenic#
ability)# can# be# collected# and# genomic# DNA# will# be# isolated# for# whole# exome#
sequence#(WES).#
WGS#analysis#will#be#applied#to#determine#osteosarcomagenesis#associated#gene#
mutations,# structural# variations,# and# copy# number# alterations# by# comparing# the#
genome# alterations# found# across# different# tumorigenic# LFS# samples.# Potential#









3.3) Generation) and) characterization) of) iPSCs) from) LFS) patients) with)
heterozygous)TP53)mutation.)
In# order# to# understand# LFS9associated# osteosarcoma# pathogenesis,# iPSCs#
generated#from#a#LFS#family#and#two#unaffected#individuals#were#used#in#this#study.#
These# iPSC# lines# were# generated# from# our# previous# studies(122),# three# LFS#





the# G245D# mutation# is# found# on# LFS# patient# fibroblasts.# (B)# The# LFS# family#




In# addition# to# the# already# established# LFS# iPSCs# line# carrying# heterozygous#
G245D#mutation,#LFS#iPSC#bank#were#expanded#by#generating#iPSC#lines#from#
affected# LFS# patient# carrying# a# different# heterozygous# TP53# mutation,# Y205C#
(TAT>TGT)# (Figure) 9A).# The# ability# of# these# patient9derived# iPSCs# in#










iPSC#clones#examined#by#RT9PCR#using# specific# primers#were#all# free#of#SeV#
genome#and# four# transgenes# (Figure)10A).#The#LFS#clones#also#maintained#a#
normal#karyotype#(Figure)10C).#
LFS# iPSCs# highly# express# pluripotency# factors# (NANOG,# OCT4)# and# hESC#
markers# (SSEA4#and#TRA91981)# (Figure)10D).# LFS# iPSCs#also#highly#express#





Figure) 9.) Generation) of) additional) LFS) iPSC) from) LFS) patient) carrying)
heterozygous)TP53)mutation.)
(A)#Schematic#diagram#of#iPSC#generation.#LFS#patient’s#fibroblast#carrying#carry#

























Multipotent# mesenchymal# stem# cells# (MSCs)# can# give# rise# to# bone,# cartilage,#
muscle,#and#adipose#tissues.#Human#osteoblasts#can#be#induced#from#MSCs.#To#
model# LFS# associated# osteosarcoma,# LFS# iPSCs# were# first# differentiated# into#
MSCs#using#PDGF9AB#based#differentiation#protocols#(191,#192).##
iPSCs# are# maintained# on# MEFs# for# at# least# 14# days# before# initiating# MSC#
differentiation# (Figure) 11A).# Although# a# lot# of# cell# death# happen# during# MSC#
differentiation,#masses#of#differentiated#cells#are#visible#on# the#cell#culture#plate#
and#fibroblast9like#MSCs#at#the#edge#of#the#cell#masses#can#be#observed#at#Day#
28# (Figure)11B).#After#subculturing# the#differentiated#cells# in#MEF/MSC#culture#
medium,# differentiated# MSCs# proliferate# quickly# and# show# fibroblast9like#
morphology#around#Day#35,#and#then#gradually#present#an#elongated#shape#and#
form#a#swirl9like#pattern#at#Day#40#(Figure)11B).#Differentiated#LFS#MSCs#express#






(A)# Schematic# diagram# of# PDGF9AB9induced# MSC# differentiation.# (B)# Cell#
morphology#of#LFS#iPSC9derived#MSCs#at#differentiation#Day#28,#Day#36,#and#Day#













following# the# protocol# showing# in# Figure) 12A.# When# MSCs# are# subjected# to#









and# mature# osteoblast# (PTH1R# and# BGLAP)# genes# were# all# increased# during#








analysis# demonstrates# the# increased# expression# of# pre9osteoblast# (ALPL# and#
COL1A1)#and#mature#osteoblast#(PTH1R#and#BGLAP)#genes#during#osteogenic#











Figure) 14.) Soft) agar) assay) confirmed) in) vitro) tumorigenic) ability) of) LFS)
derived)osteoblasts.)
In'vitro#soft#agar#assay#demonstrates#colonies#formed#in#LFS#OBs#but#not#in#WT#










In# our# collaborative# study# (193),# genome9wide# transcription# analysis# revealed#
differentially#expressed#genes#pattern#during#MSCs#to#OBs#differentiation#between#
WT# and# LFS# patient# groups# (Figure) 16A*).# Secreted# frizzled9related# protein# 2#
(sFRP2)# showed# the# greatest# fold# change# (>30),# and# was# identified# as#
overexpressed# gene# with# potential# implication# in# osteosarcoma# development#
(Figure) 16A*).# sFRP2# is# also# enriched# in# the# signature# gene# list# of# an#
osteosarcoma# tumor# initiating# cell# data# set# (GSE33458).# RT9PCR# analysis#











hand,#suppressed# tumor# formation# (Figure)16D*).# In#p53#mutant#osteosarcoma#
cell#line#HOS,#neutralizing#secretory#protein#SFRP2#with#a#monoclonal#anti9SFRP2#
antibody#significantly#reduced#tumorigenesis#as#demonstrated#in#the#CAM#assay#
(Figure) 16D*).# These# results# demonstrate# that# overexpression# of# SFRP2#
contributes#to#LFS9associated#tumorigenesis#and#osteosarcoma#development.#
High#expression#of#SFRP2#in#human#osteosarcoma#samples#correlated#with#poor#
survival# (Figure) 16E*).# Further# study# demonstrated# sFRP2# overexpression#










indicated# time#points#of#OB#differentiation.# (B)#Relative#expression#of# sFRP2# in#
MSCs#and#OBs#derived# from#LFS# iPSCs#carrying#a#heterozygous#P53p.Y205C#
mutation# compared# to# WT.# Note# that# The# LFS# iPSCs# are# generated# from# a#














overexpressed# gene# that# is# also# enriched# in# the# signature# gene# list# of# an#
osteosarcoma#gene#set#(GSE33458).#(B)#Quantitative#PCR#analysis#and#western#
blotting#of#SFRP2#expression#in#LFS#and#WT#MSCs#(*,#p9value<0.05]#**,#p9value#





antibody.# (E)# Survival# analysis# of# osteosarcoma# patients# linked# to# the# tissue#













reach# full# confluence# on# culture# dish# and# usually#marks# the# end# of# osteogenic#
differentiation#process.#
Based# on# the# central# hypothesis# of# this# study,# I# proposed# to# test# whether#
differentiated# osteoblasts# can# continue# proliferating# by# subjecting# MSCs# to# a#


















under# continuous# culture# in' vitro# exhibit# increased# tumorigenic# ability,# but# also#























To# examine# whether# LFS# OBs# are# able# to# gain# in' vivo# tumorigenesis# ability,#
subcutaneous# injection# of# LFS# derived# osteoblasts# into# NU/NU# mice# were#
performed#(Figure)18A).#In#our#previous#study#(122),#LFS#OBs#can#form# in'vivo#
tumors# but# WT# OBs# cannot.# Consistent# with# previous# study,# tumors# can# be#
observed#6910#weeks#after#subcutaneous#injection#of#LFS#(P53#p.G245D)#derived#
osteoblasts# (Figure) 18B).# The# LFS# osteoblast9derived# tumors# demonstrated#
immature# osteoblast# characteristics,# positive# AP# activity# (AP# staining),# positive#
collagen#matrix# deposition# (picrosirius# red# staining)# but# negative#mineralization#
(von#Kossa#staining)#(Figure)18C).#The#LFS#xenograft#tumor#model#demonstrates#




19A).#However,# tumor# formation#was# not# observed# in# five# LFS# (P53# p.G245D)#
derived#osteoblast#lines#injected#intratibially#(Figure)19A).##
The#osteoblasts#later#than#differentiation#Day#14#may#aggregate#and#be#difficult#to#
dissociate# due# to# the# huge# accumulations# of# collagens# and# other# bone#matrix#





time# point# for# in' vivo# tumorigenesis# assay.# We# also# performed# subcutaneous#
injection#of#LFS9derived#osteoblast#at#differentiation#Day#7#(Figure)19B).#Out#of#
five#LFS#(P53#p.G245D)#derived#osteoblast#lines,#only#LFS#39A#line#were#able#to#
generate# grossly# visible# tumors:# total# 14# injections# were# performed,# 5# grossly#
visible#tumors#were#observed.#No#tumor#formation#was#observed#in#other#four#lines.#













Five# first9round# tumors#successfully#generated# from#LFS#39A# line#were# isolated#
(Figure) 20A)# and# expanded# in# culture.# Histological# examination# demonstrated#












deposits,# respectively.# The# LFS9derived# tumors# represent# immature# osteoblast#
































ends# (Figure) 21B).# The# detail# statistics# for# the# quality# of# sequencing# data# are#













are# in#more#advanced#stage# in# tumor#development#or#contain#sub9population#of#
 86#





Day# 7# and# Tumor## 4# (Figure) 22C).# By# overlapping#mutated# genes# from# three#
tumor#cell# lines,#we#found#one#gene#(GABRR2)#are#commonly#mutated# in# three#
tumor# cell# lines.# Interestingly,# all# three# tumor# cells# line# carried# same#
nonsynonymous# mutation# on#GABRR2# (c.G227T,# p.A76S)# (Figure) 23A).# One#
hypothesis#is#that#the#mutation#already#exists#in#MSCs#or#OB#Day#7.#We#checked#
the#BAM# file,# and#no#alternative# reads#were# identified# in#MSCs,#while# very# low#
signal#of#alternative# read#were#detected# in#OB#sample.#There# is#an# increase# in#
allele#frequency#of#this#variant#on#GABRR2#in#tumor#derived#cell#lines#(Figure)23B).#
One#explanation#is#that#this#mutation#occurs#during#osteogenic#differentiation,#and#
may# contribute# to# growth# advantage# during# tumor# formation# process.#GABRR2#
(gamma9aminobutyric#acid#type#A#receptor#rho2#subunit)#encodes#a#member#of#the#
rho# subunit# family# and# is# a# component# of# the#GABA# type#A# receptor# complex.#
GABA#is#a#well9known#inhibitory#neurotransmitter#in#the#mammalian#brain#where#it#
acts#at#GABA#receptors#(197).#GABRR2#are#highly#expressed#in#brain#tissue,#while#
the#expression# level# is#quite# low# in#osteoblasts# (in#house#database).#Therefore,#




commonly# mutated# in# Tumor# #4# and# Tumor# #5# (Figure) 22C).# Genes# carrying#
nonsynonymous#mutations#are#bolded#in#the#list.##
Utilizing#a#web9based#application#MusiCa,#which#is#used#to#characterize#mutational#
signatures# in# cancer# samples# (186,# 198),# we# examined# somatic# mutation#
prevalence#in#OB#Day#7#sample#and#three#tumor9derived#cell#lines.#As#shown#in#
Figure)24A,#somatic#mutations#are#more#prevalent#in#tumor9derived#cell#lines#when#
compared# to# osteoblasts.#Figure) 24B# are#CIRCOS#plots# summarizing# variants#
identified#as#non9frameshift#substitution,#frameshift#substitution,#nonsynonymous#

















(A)# Diagram# illustrating# workflow# of# whole# exome# sequencing,# including# data#
cleanup#and# variant# discovery.# (B)#Representative# figure# showing#quality# score#























(A)#Somatic#mutation#prevalence# in#OBs#and# three# tumor9derived#cell# lines.# (B)#
CIRCOS#plots#summarizing#variants#identified#in#OBs#and#three#tumor9derived#cell#
lines.#From#outer# line#to#inner# line#depicting#information#regarding#chromosome,#
gene,# variant# type# (non9frameshift# substitution,# nonsynonymous# SNV,# stopgain#
and#frameshift#substitution),#alternative#allele#count#in#sample#(scale#from#0930),#
alternative#allele#count#in#MSCs#(0930),#SIFT#score#(091)#and#PolyPhen2#score#(09
1).# (C)# Pathway# analysis# of# mutated# genes# (non9frameshift# substitution,#
nonsynonymous#SNV,#stopgain#and#frameshift#substitution)#identified#in#OBs#and#

















derived# MSCs# and# OBs# at# different# differentiation# time# point.# Prevalence# of#
 97#
missense#mutation,# truncating#mutation,# amplification# and# deletion# of# identified#
genes#in#human#cancers#are#demonstrated#in#bar#plot.#Data#were#obtained#from#











A# study# carried# out# by# Alexandrov#et' al.# (198)# extracted#mutational# signatures#




Using# this# 969substitution# classification,# more# than# 20# distinct# mutational#
signatures# are# identified# in# human# cancers.# Based# on# this# study,# we# also#
characterized#mutational# signatures# in#osteoblasts#and# three# tumor9derived# cell#
lines#using#a#web9based#application#MusiCa#(186).#We#observed#a#prevalence#of#
C>T# mutations# in# both# OBs# and# tumor9derived# cell# lines# (Figure) 25A).# When#
comparing#mutational#signature#of#LFS#OB#and#OB9derived#tumors#with#different#
human#cancer# types,#we#observed#presence#of#Signature#3#and#30#both# in#our#










(data#obtained# from#http://cbioportal.org)# (200)#and#expression# level#of#some#of#
 99#
these# genes# are# associated# with# patient# overall# survival# (data# obtain# from#
http://gepia.cancer9pku.cn/index.html)# (201).# We# summarized# the# potential#




Gene$ Sample$ Mutation$ Predicted$effect$
AA/Sequence$
Change$ SIFT$ PolyPhen2$ ClinVar$
IGSF11# Tumor##2,#5# chr3:118623502:C>A# stopgain# p.E283X# 0.08# NA# NA#
SLC35G2# Tumor##2# chr3:136573705GGGT# stopgain# p.E135X# 0# NA# NA#
TTK# Tumor##2# chr6:80747711:G>T# stopgain# p.E692X# 0# NA# NA#
ZNF365# Tumor##2# chr10:64136574:A>T# stopgain# p.K208X# 1# NA# NA#
SDK2# Tumor##2# chr17:71468309:G>T# stopgain# p.C91X# NA# NA# NA#
HRNR# Tumor##4# chr1:152193815:G>T# stopgain# p.S97X# 1# NA# NA#
FSIP2# Tumor##4# chr2:186696609:G>T# stopgain# p.E6952X# 0.12# NA# NA#
CDC20B# Tumor##4# chr5:54439369:C>T# stopgain# p.W153X# 0.2# NA# NA#
FDXACB1# Tumor##4# chr11:111745843:G>A# stopgain# p.R560X# 1# NA# NA#
GOLGA6L1# Tumor##4# chr15:22743596:C>T# stopgain# p.Q649X# 0.65# NA# NA#
FAM20A# Tumor##4,#5# chr17:66536085:A>C# stopgain# p.Y276X# 1# NA# NA#
KMT2C# Tumor##5# chr7:151873299:G>T# stopgain# p.S3080X# 1# NA# NA#
SLC25A32# Tumor##5# chr8:104427097:A>C# stopgain# p.Y23X# 1# NA# NA#
SYNE2# Tumor##5# chr14:64691257:C>T# stopgain# p.R343X# 1# NA# NA#
























# # # # # # # #
GABRR2# Tumor##2,4,5# chr6:89981436:C>A# missense# p.A76S# NA# 0.977# NA#
ANKRD36B# Tumor##2,#5# chr2:97820413:T>A# missense# p.C399S# 0.77# 0# NA#
USP34# Tumor##5# chr2:61441611:A>G# missense# p.F2756L# 0.1# 0.878# NA#
ANAPC1# Tumor##2,#5# chr2:112615888:C>G# missense# p.Q451H# 0.18# 0.005# NA#
ESPL1# Tumor##5# chr2:61441611:A>G# missense# p.F366L# NA# 0.039# NA#
MUC16# Tumor##2,#5# chr19:9059734:G>C# missense# p.P9238A# 0# 0.003# NA#
USH2A# Tumor##4,#5# chr1:216371841:G>T# missense# p.S1299R# 0.11# 0.761# NA#
MYLK# Tumor##4# chr3:123359161:T>G# missense# p.I1535L# 0# 0.378# NA#
MYLK# Tumor##5# chr3:123383051:T>G# missense# p.T1227P# 0.01# 0.984# NA#
TRPC7# Tumor##4# chr5:135692438:C>A# missense# p.S213I# 0# 0.995# NA#





We$ showed$ that$ LFS$ patient4derived$ iPSCs$ and$ their$ MSCs/OBs$ provide$ a$
platform$for$investigating$the$early$development$of$LFS4associated$osteosarcoma,$
and$identified$potential$candidate$genes$in$driving$osteosarcoma$development.$











factor,$ and$ overexpression$ of$ SFRP2$ exerts$ oncogenicity$ in$ LFS$ derived$OBs.$
Further$ study$ by$ Kim$ et# al$ (193)$ indicate$ SFRP2$ can$ promote$ osteosarcoma$
phenotype$by$inducing$angiogenesis$and$oncogenic$molecules$such$as$FOXM1#






tumors$ while$WT$OBs$ cannot.$ In$ this$ study,$ we$ carried$ our$ several$ rounds$ of$
injection$in$immunocompromised$mice$to$establish$xenograft$model.$Generation$of$
orthotopic$xenograft$model$ in$SCID$mice$was$unsuccessful.$One$of$ the$ reason$
might$due$to$limited$cell$numbers$(2$x$106)$can$be$injected$intratibially$as$intratibial$




Another$ explanation$ is$ that$ LFS$ 34A$ line$ might$ already$ harbor$ some$ driver$
mutations$which$ give$ cells$ in# vivo$ growth$ advantage.$ It$would$ be$ interesting$ to$
sequence$other$cell$ lines,$ for$example$LFS$34C$derived$OBs,$and$compare$ the$
different$genetic$profiles$between$cell$lines,$which$might$also$aid$in$osteosarcoma$
driver$genes$identification.$In$addition,$the$overall$low$tumor$formation$rate$of$LFS$
derived$ OBs$ indicate$ that$ these$ cells$ are$ not$ malignant$ cells$ yet.$ Therefore,$
sequencing$the$LFS$OB4derived$tumor$cell$lines$can$help$identifying$driver$events$
during$osteosarcoma$initiation.$
Previous$ study$ (199)$ used$ Sleeping# Beauty$ transposon$ mutagenesis$ to$ drive$
osteosarcomagenesis.$This$forward$genetic$screening$enable$the$identification$of$
hundreds$ of$ significant$ CIS4associated$ genes$ that$ likely$ to$ be$ drivers$ of$
osteosarcoma$development.$Here,$we$present$a$different$approach$in$identifying$
driver$ genes$ during$ osteosarcomagenesis$ by$ sequencing$ LFS$ patient4derived$
cells$with$different$oncogenic$potentials,$including$MSCs$(no$tumorigenic$ability),$
 104$
osteoblasts$ (gaining$ tumorigenic$ ability),$ and$ osteoblast4derived$ subcutaneous$
xenograft$ (retaining$ in# vivo$ tumorigenic$ability).$ In$ pathway$analysis$ of$mutated$
genes$ of$ our$ LFS$ OB4derived$ tumors,$ we$ did$ not$ observe$ enrichment$ of$
PI3K/mTOR,$ErbB$or$ERK4MAPK$signaling$as$previous$identified$osteosarcomas$
in$other$studies$(199,$204).$In$the$context$of$LFS$associated$osteosarcoma,$our$
model$ aims$ at$ discovering$ initial$ driver$ event$ during$ LFS4associated$
osteosarcomagenesis$and$the$collected$LFS$OBs$and$OB4derived$tumor$cell$lines$
are$not$ really$at$advanced$malignant$stage,$ it$ is$possible$ that$ the$characterized$


















moderately$ or$ highly$ in$ OBs,$ including$ USP34,$ ESPL1$ and$ MYLK.$ We$ also$
observed$genes$carrying$stopgain$or$frameshift$mutation$in$our$LFS$OB4derived$
tumors,$including$SLC35G2,$FAM160A2,$SLC25A32,$SYNE2,$RPL8,$and$FAM20A.$
Reported$functions$of$ these$genes$are$summarized$ in$Table$13$ in$Chapter$6.1.$
These$ genes$ are$ potential$ candidate$ driver$ genes$ during$ early$ osteosarcoma$












onset$ is$ under$ 35$ years$ (2084210).$ According$ to$ IARC$ TP53$ Database$
(http://p53.iarc.fr/),$breast$cancer$is$also$the$most$common$tumor$among$women$











A$number$of$ transplantation$experiments$ (2164218)$ suggested$ the$existence$of$
mammary$gland$stem$cells$(MaSCs),$in$which$fragments$of$mammary$tissue$could$
reproduce$the$entire$epithelial$ductal$trees$in$the$clear$fat$pad$of$recipient$mice.$
Single4cell$ lineage4tracing$ experiments$ have$ also$ revealed$ the$ multipotency$ of$
MsSCs:$a$single$MaSC$can$contribute$ to$ the$ formation$of$ the$ductal$epithelium$
(during$puberty)$(219,$220)$and$of$the$alveolar$epithelium$(during$lactation)$(219).$$
Several$ mouse$ model$ studies$ also$ suggested$ the$ potential$ role$ of$ MaSCs$ in$





can$be$used$ to$model$ and$ study$ cancer.$ In$ this$ chapter,$ I$ hypothesize$ that$ by$
differentiating$ LFS$ patient$ derived$ iPSCs$ into$ mammary$ gland$ stem$ cells$ or$
progenitor$ cells,$ LFS$ patients$ associated$ breast$ cancer$ can$ be$ modelede$









nucleotide$deletion$ (delG)$at$exon$9$and$ intron$9$ junction$of$TP53# (c.993delG).$
One$of$the$proband’s$daughter$(3648T)$was$also$diagnosed$with$LFS$carrying$this$
single$ nucleotide$ deletion$ (delG).$ The$ other$ daughter$ (3650T)$ is$ a$ healthy$
individual$with$wild$ type$TP53$ and$were$used$as$a$normal$control$ in$ this$study$
(Figure$28A,$28B).Three$fibroblasts$were$reprogramed$using$Yamanaka$factors$
as$ illustrated$ in$ Figure$ 9A.$ The$ ability$ of$ these$ patients’$ derived$ iPSCs$ in$
differentiating$into$mammary$stem$cells$(MaSCs)$or$mammary$epithelial$cells$will$
provide$platform$for$modeling$breast$cancer.$$
Three$ iPSC$clones$generated$ from$proband$ (3649T)$ named$C3,$C14$and$C17$













abnormal$ karyotype:$ B1$ clone$ showed$ trisomy$ 6,$ B2$ and$ B3$ clones$ showed$
trisomy$5$(Figure$28D).$Due$to$abnormal$karyotype,$iPSC$clones$B1,$B2$and$B3$
generated$ from$carrier$ (3648T)$were$not$ further$ characterized$and$used$ in$ this$
study.$$
Further$characterization$of$the$iPSC$clones$generated$from$LFS$patient$3649T$and$
unaffected$ relative$ 3650T$ indicated$ all$ seven$ clones$ exhibit$ the$ typical$ hESC$
morphology$ and$ show$ the$ positive$AP$activity$ (Figure$ 29A).$ LFS$patient$ iPSC$
clones$also$highly$express$pluripotency$ factor$mRNAs$ (NANOG,$OCT4,$SOX2,$
DPPA4,$and$REX1),$comparable$to$hESC$H1$line$and$much$higher$than$parental$
fibroblasts$ (Figure$ 30B).$ Immunofluorescent$ staining$ showed$ these$ generated$
iPSC$clones$all$highly$express$pluripotency$factors$(NANOG,$OCT4)$and$hESC$
markers$(SSEA4$and$TRA41481)$(Figure$30A).$
Subcutaneous$ injection$of$LFS$and$WT$iPSC$clones$ in$NU/NU$mice$resulted$ in$
teratoma$ formation.$ Histological$ analysis$ indicated$ that$ teratoma$ formed$ from$
iPSC$ clones$ contain$ embryonic$ tissues$ of$ all$ three$ germ$ layers$ (Figure29B),$














































between$ individuals$ (even$between$ relatives).$ To$better$ reveal$ this$mutant$ p53$
(delG)$related$phenotypic$differences$and$minimize$the$variability$between$patient$
and$healthy$individual$derived$iPSC$lines,$we$aimed$to$generate$isogenic$controls$
by$ either$ correcting$TP53$ mutation$ (delG)$ using$ patient$ (3649T)$ derived$ iPSC$
clones$ or$ creating$ this$ single$ nucleotide$ deletion$ (delG)$ in$ unaffected$ daughter$





The$mutant$ and$WT$donor$ vectors$were$ constructed$ using$ pFNF$donor$ vector$
carrying$a$Frt4EM74NeoR4Frt$(FNF)$selection$cassette$flanked$by$1$kb$left$and$right$
homologous$ arms$ of$ the$ TP53# genomic$ region$ and$ primers$ used$ to$ identify$
correctly$inserted$colonies$are$shown$with$arrows$(Figure$31B).$$
To$ test$ the$ potential$ efficiency$ of$ designed$ TALEN$ guides$ and$ CRISPR/Cas9$
guides,$these$vectors$were$transfected$as$pairs$in$to$293T$cells.$The$transfection$
efficiency$was$satisfactory$as$indicated$by$concurrent$transfection$of$control$vector$






resistant$ clones$ were$ confirmed$ by$ genomic$ PCR$ using$ two$ pairs$ of$ primers$
(p53_4FM13$and$3FNF4N1$for$left$arm,$5FNF4C1$and$3p53_17099$for$right$arm)$
(Figure$ 31B).$ Total$ 154$ and$ 160$ clones$were$ picked$ for$ TALEN$ pair$ 1$ and$ 2$
respectively,$however,$none$of$ the$clones$were$correctly$ inserted$(Figure$32A).$




to$ previous$ results,$ all$ three$ clones$ showed$ low$ insertion$ rate$ (less$ than$ 5%)$








of$ experiment$ were$ performed$ for$ each$ clone$ with$ different$ amount$ of$ TALEN$
guides$ transduced$ illustrated$ in$Figure$33A.$ The$overall$ correct$ insertion$ rates$
 117$
were$between$15%$to$27%$ in$both$clones$ (Figure$33A).$The$correctly$ inserted$
clones$were$confirmed$by$genomic$PCR$using$two$pairs$of$primers$(p53_4FM13$
and$3FNF4N1$for$left$arm,$5FNF4C1$and$3p53_17099$for$right$arm),$as$shown$in$
representative$ graph$ (Figure$ 33B).$ The$ correctly$ inserted$ clones$ were$ also$
checked$by$PCR$amplification$of$exon$8$and$9$of$TP53$using$primer$p53_8/9FM13$
and$p53_8/9RM13:$clones$with$positive$band$indicated$that$insertion$was$only$in$

















creating$mutant$ p53$ (delG)$ using$ TALEN4mediated$ or$ CRISPR/Cas94mediated$


























with$ single$ insertion,$ carrying$either$ desired$TP53#mutation$or$ no$mutation.$ (F)$









developed$ a$ two4step$ wise$ protocol$ enable$ differentiation$ of$ human$ iPSCs$ to$
mammary4like$ organoids,$ providing$ an$ iPSC4based$model$ for$ studying$ function$
and$regulation$of$normal$mammary$cell$(226).$To$further$explore$LFS4associated$
breast$ cancer$ using$ iPSC$ based$ model,$ we$ aim$ to$ induce$ mammary$ lineage$
differentiation$following$protocol$described$by$Qu$et#al.$group$(226).$
Formation$of$ embryoid$bodies$ (EBs)$ from$ iPSCs$or$ hESCs$ is$ broadly$ used$ for$
direct$ differentiation.$ However,$ in# vitro$ studies$ have$ shown$ that$ EBs$ formation$
preferentially$ induces$neural$ectoderm$ from$ iPSCs/hESCs$ (227).$Enrichment$of$
non4neural$ ectoderm$ cells,$ the$ origin$ of$ mammary$ stem$ cells,$ during$ initial$
differentiation$stage$is$therefore$critical.$




Instead$ of$ low$ attachment$ plates,$ AggreWell$ were$ used$ in$ our$ experiments$ to$
facilitate$ embryoid$ bodies$ formation$ (Figure$ 34B,$ 35A).$ The$ classic$ embryoid$
bodies$ formation$were$performed$ in$parallel$as$control$ (Figure$34,$35).$To$ test$
















results$ indicated$ that$ neural$ and$ non4neural$ ectoderm$ cells$ coexist$ at$ 104day$
embryoid$ bodies$ stage,$ both$ in$ EBs$ and$ mEBs.$ On$ our$ hand,$ MammoCult$
medium4cultured$EBs$(mEBs)$expressed$non4neural$ectoderm$marker,$however,$





with$MammoCult$medium$ in$ AggreWell$ for$ 12$ days,$ and$mEBs$were$ collected$
 125$
every$ three$days$and$reattached$for$ immunostaining.$For$both$C3$and$C14$ line$
(data$of$C14$line$not$shown$here),$non4neural$ectoderm$marker$AP42γ$and$CK18$
started$ to$ express$ in$ 34day$ mEBs$ (Figure$ 35,$ 26).$ The$ percentage$ of$ AP42γ$
positive$cells$slightly$increased$during$the$124day$mEB$formation,$and$more$than$
50%$of$reattached$cells$express$AP42γ$around$day$10$(Figure$35).$More$than$50%$
of$ the$ cells$ were$ of$ CK18$ positive$ at$ day$ 3,$ and$ no$ significant$ increase$ of$
percentage$ of$ CK18$ positive$ cells$ were$ observed$ during$ 124day$ differentiation$
(Figure$ 36).$ In$ our$ experimental$ setting,$ non4neural$ ectoderm$ marker$ started$






























































Figure$ 38.$ Two$ step$ differentiation$ of$ mammary:like$ organoids$ from$ LFS$
iPSCs.$
(A)$Western$blot$of$AP42γ$and$CK18$expression$in$LFS$iPSCs$and$hESCs,$and$















In# vitro$ modeling$ of$ LFS$ associated$ malignancy$ (osteosarcoma)$ has$ been$
facilitated$by$LFS$patient$derived$iPSCs$(122,$193).$“Bone$tumor$in$a$dish”$model$










self4renewal$ and$ give$ rise$ to$ daughter$ neoplastic$ cells$ that$ form$ tumors$ (230),$
resembling$ MaSCs$ characteristic.$ Experimental$ data$ showed$ that$ both$ breast$
cancer$ tissue$ and$ normal$ human$mammary$ gland$ are$ hierarchically$ organized$
(231),$and$data$from$hierarchy$model$indicates$that$a$rare$population$of$mammary$
cells$ is$more$ tumorigenic$ than$a$non4stem$cell$population$ (232),$supporting$ the$
hypothesis$ that$ breast$ cancer$ originates$ from$ BCSCs.$ However,$ there$ are$ still$
intense$ debates$ about$ whether$ BCSCs$ are$ derived$ from$ MaSCs,$ transformed$
progenitor$cells$(more$differentiated$cells)$or$both.$$
Some$ researchers$ hypothesize$ that$ accumulation$ of$ genetic$ mutation,$ either$
activating$oncogenes$or$inactivating$tumor$suppressor$during$MaSCs$self4renewal$
 135$
and$ expansion$ can$ lead$ to$ unregulated$ differentiation$ and$ proliferation,$
contributing$to$carcinogenesis$of$breast$tissue.$Transcriptome$analyses$of$mouse$
mammary$cell$subpopulation$revealed$tumors$developed$in$MMTV4Wnt41$and$p534
/4$ mice$ were$ enriched$ for$ MaSC4subset$ genes$ (CD29hiCD24loCD61+)$ (223),$






are$ clonally$ expanding$ (233,$ 234),$ suggesting$ these$ more$ differentiated$ and$
committed$ progenitor$ cell$ may$ also$ be$ targets$ during$ carcinogenesis.$ Several$
studies$implied$that$luminal$progenitor$cells$might$be$the$targets$of$transformation$















need$ in$ directed$ differentiation$ protocols$ for$ a$ broader$ set$ of$ cancer$ types,$
including$breast,$ovary$and$prostate.$
Currently,$a$robust$and$consistent$directed$differentiation$protocols$of$breast$tissue,$
either$ for$ mammary$ stem$ cells$ (MaSCs)$ or$ mammary$ glands$ have$ not$ been$
established.$In$this$study,$we$tried$to$differentiate$LFS$derived$iPSCs$to$mammary4
like$organoids$using$a$two4step$wise$protocol$developed$by$Qu$et#al.$in$2017$(226).$
This$ protocol$ is$ primarily$ established$ using$ iPSCs.$ However,$ it$ worked$ in$ low$
efficiency$in$our$hands$for$LFS$iPSCs.$Different$genetic$background$of$iPSC$lines$





low$ efficiency$ in$ forming$ branching4like$ structured$ mammary$ organoids$ in$ 3D$






















As$ previously$ illustrated$ in$ Chapter$ 4.2,$ precise$ genome4editing$ tools$ such$ as$
TALENs$ and$CRISPR/Cas9$ can$ be$ used$ to$ generate$ isogenic$ control$ for$ LFS$
iPSCs.$TALEN$and$CRISPR/Cas9$guides$targeting$exon$7$of$TP53$were$designed$
(Figure$40A)$for$correcting$mutant$p53$(G245D)$in$LFS$iPSCs$(cell$line$described$
in$ Chapter$ 3).$ The$ overall$ insertion$ rate$ (correctly$ inserted$ in$ TP53$ locus)$ for$














TALEN$ guides$ targeting$ intron$ 5$ of$ TP53$ were$ designed$ (Figure$ 41A)$ for$
correcting$ mutant$ p53$ (Y205C)$ in$ LFS$ iPSCs.$ The$ WT$ donor$ vectors$ were$
constructed$using$pFNF$donor$vector$carrying$a$Frt4EM74NeoR4Frt$(FNF)$selection$
cassette$ flanked$by$1$ kb$ left$ and$ right$ homologous$arms$of$ the$TP53#genomic$
region$ and$ primers$ used$ to$ identify$ correctly$ inserted$ colonies$ are$ shown$with$
arrowse$the$expected$size$of$PCR$product$are$shown$in$the$table$(Figure$41A).$
LFS$iPSC$A8$clone$were$used$for$mutant$p53$(Y205C)$correction.$The$correctly$








blot$ indicated$that$5$clones$of$7$carried$single$ insertion$(Figure$42B)$ located$ in$
TP53#genomic$region$(shown$in$yellow$arrows).$$Sanger$sequence$of$the$5$single$













TP53# locus.$ (B)$ Number$ of$ inserted$ clones$ were$ picked$ from$ LFS$ iPSC$ lines$
transduced$with$WT$p53$donor$vector$and$TALEN$guides.$(C)$Number$of$inserted$
clones$ picked$ from$LFS$ iPSC$ lines$ transduced$with$WT$ p53$ donor$ vector$ and$




























cassette$can$either$be$ inserted$ into$WT$allele$or$mutant$allele.$Only$ the$picked$






To$provide$a$useful$ lab$ resource$ for$modeling$mutant$ p534related$ cancers$ and$
diseases,$ we$ generated$ a$ H1$ human$ embryonic$ stem$ cell$ line$ carrying$ a$
homozygous$ R282W$ mutation$ of$ TP53$ (one$ of$ the$ hotspot$ mutations)$ using$
TALEN4mediated$genome$editing$(Figure$43A).$TALEN$target$sites$are$in$bold$red.$
Start$sites$of$the$upstream$and$downstream$homologous$arms$are$underlined.$The$
design$ of$ the$ mutant$ donor$ vector$ is$ also$ illustrated.$ Primers$ used$ to$ identify$
correctly$inserted$colonies$are$shown$with$arrows.$
hESC$H1$cells$were$transfected$by$electroporation$with$paired$TALEN$plasmids$
and$ a$ R282W$ donor$ vector$ containing$ a$ Frt4EM74NeoR4Frt$ (FNF)$ selection$
cassette.$The$electroporated$cells$were$selected$by$G418$(Geneticin).$The$G4184
resistant$ clones$ were$ picked$ up,$ isolated,$ and$ expanded.$ The$ TP53$ targeted$
regions$ were$ analyzed$ by$ PCR$ (Figure$ 43B)$ using$ two$ pairs$ of$ primers$










9.$Unexpectedly,$PCR/Sanger$sequencing$of$ the$exon$8/9$ region$ revealed$ that$
clone$1R5$contains$a$R282W$mutation$in$both$alleles$(only$TGG$rather$than$(T/$
C)GG$in$the$mutated$exon$8/9$region)$(Figure$43C).$The$possibility$of$additional$
R282W$mutation$ in$ the$unengineered$allele$ is$due$ to$spontaneous$homologous$
recombination4mediated$ mutagenesis$ by$ the$ R282W$ donor$ vector.$
Immunoblotting$ results$ revealed$ the$ increased$ level$ of$ p53$ in$ R4418$ and$ 1R5$
clones$ in$ comparison$ with$ that$ of$ parental$ H1$ cells$ (Figure$ 43D),$ suggesting$
mutant$p53(R282W)$is$more$stable$than$wild4type$p53.We$rename$the$1R5$line$to$
H14p53(R282W/R282W).$




Quantitative$ real4time$ PCR$ (qRT4PCR)$ analysis$ showed$ comparable$ mRNA$
expression$ of$ pluripotency$ genes$ (NANOG,$ OCT4,$ SOX2,$ DPPA4,$ REX1$ and$




In$ summary,$ H14p53(R282W/R282W)$ cells$ maintain$ a$ pluripotent$ state$ with$ a$
normal$ karyotype.$ This$ line$ provides$ a$ useful$ resource$ to$ study$ p53(R282W)4





Figure$ 43.$ Establishment$ and$ characterization$ of$ the$ homozygous$ p53$
R282W$mutant$human$embryonic$stem$cell$line$H1:p53(R282W/R282W).$$
(A)$Schematic$diagram$of$the$strategy$for$p53(R282W)$generation.$TALEN$target$
sites$ are$ indicated$ in$ bold$ red.$ Start$ sites$ of$ the$ upstream$ and$ downstream$
homologous$arms$are$underlined.$(B)$PCR$of$precise$homologous$recombination$
in$TP53$genome$loci.$(C)$Sequences$of$the$homozygous$p53(R282W)$mutation$in$
H14p53(R282W/R282W)$ cell$ line.$ (D)$ Immunoblotting$ of$ the$ p53(R282W)$
expression$ in$ cell$ line$ R4–18$ and$ 1R5$ (H14p53(R282W/R282W)).$ (E)$ Cell$
morphology$and$AP$staining$of$H14p53(R282W/R282W)$cell$line.$Scale$bar,$50$μm.$
(F)$Immunofluorescence$staining$of$pluripotency$markers$NANOG,$OCT4,$SSEA4$
and$TRA41481$ in$H14p53(R282W/R282W)$cell$ line.$Scale$bar,$50$μm.$ (G)$qRT4








We$ also$ generated$ a$ H1$ hESC$ line$ harboring$ a$ homozygous$ TP53$ R248W$





















larger$ PCR$ band$ of$ the$ TP53$ exon$ 7$ region$ of$ the$ FNF4removed$ clone$ 1P6$
demonstrated$the$footprint$of$Frt,$which$was$all$that$remained$after$excision$from$
the$ FNF$ cassette4inserted$ allele$ (Figure$ 44B,$ arrow$ in$ lower$ panel).$ Sanger$
sequencing$of$endogenous$TP53$exon$7$of$the$1P6$clone$further$confirmed$the$
presence$of$the$TP53$R248W$mutation$in$both$alleles$(Figure$44C,$lower$panel),$
consistent$ with$ the$ findings$ from$ the$ parental$ P1–36$ clone.$ Immunoblotting$
revealed$higher$p53$protein$ levels$ in$both$P1–36$and$1P6$clones$ than$ those$ in$
parental$ H1$ line$ (Figure$ 44D,$ higher$ panel),$ supporting$ the$ increased$ protein$
stability$ of$ mutp53.$ Although$ both$ P1–36$ and$ 1P6$ clones$ demonstrated$
homozygous$TP53$R248W$mutation,$higher$p53$mRNA$levels$were$measured$in$
the$1P6$clone,$explaining$the$higher$p53$protein$levels$in$the$1P6$clone$compared$
to$ the$P1–36$clone$ (Figure$44D,$ lower$panel).$We$rename$ the$1P6$ line$ to$H14
p53(R248W/$R248W).$
The$ H14p53(R248W/R248W)$ line$ maintained$ a$ classical$ dome4shaped$ hESC$
morphology$and$exhibited$positive$alkaline$phosphatase$(AP)$activity$(Figure$44E).$
Immunofluorescent$ staining$ of$ the$ H14p53(R248W/R248W)$ line$ demonstrated$
high$expression$of$hESC$pluripotency$factors$and$hESC$surface$markers$(Figure$
33F).$Although$quantitative$real4time$PCR$(qRT4PCR)$showed$lower$mRNA$levels$
of$ pluripotency$ genes$ in$ the$ H14p53(R248W/R248W)$ line$ compared$ with$ the$
parental$ H1$ line$ (Figure$ 44G),$ these$ cells$ functionally$ perform$ as$ PSCs,$ as$
demonstrated$by$their$proliferation$in$hESC$medium$as$well$as$in$vivo$three$germ4
line$differentiation$capacity$(Figure$44H).$Karyotype$analysis$confirmed$the$normal$
karyotype$ of$ the$H14p53(R248W/R248W)$ line$ (Figure$ 44I).$ Furthermore,$PCR4
 150$
based$ mycoplasma$ detection$ assay$ demonstrated$ that$ the$ H14$
p53(R248W/R248W)$ line$ is$ mycoplasma4free$ (Figure$ 44J).$ The$ short$ tandem$
repeat$ (STR)$ profile$ of$H14p53(R248W/R248W)$ line$was$ identical$ to$ that$ of$ its$
parental$H1$line$(data$not$shown$here).$
In$summary,$the$H14p53(R248W/R248W)$line$is$karyotypically$normal$and$retains$











H14p53(R248W/R248W)$ cell$ line.$ (D)$ Immunoblotting$ of$ the$ p53(R248W)$
expression$ in$ cell$ line$ P1436$ and$ 1P6$ (H14p53(R248W/R248W)).$ (E)$ Cell$
morphology$and$AP$staining$of$H14p53(R282W/R282W)$cell$line.$Scale$bar,$50$μm.$
(F)$Immunofluorescence$staining$of$pluripotency$markers$NANOG,$OCT4,$SSEA4$
and$TRA41481$ in$H14p53(R282W/R282W)$cell$ line.$Scale$bar,$50$μm.$ (G)$qRT4







As$ mentioned$ in$ Chapter$ 1,$ patient4derived$ iPSCs$ have$ been$ used$ to$ model$
various$ diseases,$ such$ as$ long4QT$ syndrome$ (LQTS)$ (165,$ 166)$ [159,160],$ α1$
antitrypsin$ (AAT)$ deficiency$ (167,$ 243)$ [161,162],$ Diamond–Blackfan$ anemia$
(DBA)$ (2444246)$ [165–167]$ and$ familial$ Alzheimer’s$ disease$ (161)$ [168].$
Successful$ cancer$ modeling$ has$ also$ been$ established$ using$ patient$ derived$
iPSCs$ (122,$ 168,$ 169).$ However,$ these$ disease$ models$ are$ generated$ from$
various$patients$who$usually$carry$differences$in$the$genetic$background,$and$most$

















mutation$ in$TP53$across$different$human$cancers.$This$mutation$ lies$within$ the$








difficulty$ in$ correcting$mutant$ p53$ (delG)$ in$ LFS$ breast$ cancer$ patient$ derived$
iPSCs$(as$described$in$Chapter$4).$It$is$also$possible$that$this$mutant$p53$(delG)$











oncogenic$ ability$ (data$ shown$ in$ chapter$ 3),$ suggesting$ this$ mutation$ is$ likely$





Missense$ substitutions$ at$ many$ “hotspot”$ sites$ confer$ novel$ cancer4promoting$





















In$ Chapter$ 3,$ we$ identified$ several$ candidate$ genes$ likely$ driving$ early$





true$ driver$ during$ osteosarcoma$ development$ or$ just$ a$ passenger.$ Since$ the$
identified$candidates$carry$either$ truncating$mutation$or$missense$mutation$ that$
predicted$to$be$damaging,$we$can$use$shRNA$to$knockdown$expression$of$each$
gene$ and$ perform$ in# vitro$ tumorigenic$ assay$ (soft$ agar)$ under$ iPSC4MSC4OB$























































































































































structure$and$ function$of$organs$ than$2D$culture$and$have$been$used$ to$model$
normal$development$as$well$as$human$diseases$(275,$276).$Interestingly,$the$3D$
organoid$culture$system$has$been$extended$ to$primary$cancer$ culture$ in$which$
cancer$ organoids$ can$ be$ generated$ from$ primary$ tumors$ including$ colon$ (277,$
278)$ ,$ pancreatic$ (279),$ and$ prostate$ cancers$ (280).$ Both$ normal$ and$ cancer$
organoids$provide$a$unique$platform$for$drug$sensitivity$and$toxicity$testing.$Mature$
proximal$ tubule$ cells$within$ iPSCs4derived$ kidney$organoids$undergo$apoptosis$
after$cisplatin$treatment,$indicating$that$kidney$organoids$could$be$used$to$test$drug$
nephrotoxicity$ (281).$ Cystic$ fibrosis$ patient4derived$ rectal$ organoids$ have$ been$
used$to$characterize$the$response$to$cystic$fibrosis$transmembrane$conductance$
regulator$ (CFTR)4modulating$ drugs,$ suggesting$ that$ organoids$ can$ be$
prospectively$used$to$identify$drug$responders$(282).$A$team$from$the$Netherlands$
generated$ a$ living$ organoid$ biobank$ from$ colorectal$ cancer$ patients$ and$
demonstrated$the$feasibility$of$high4throughput$drug$screening$while$highlighting,$
as$ an$ example$ of$ potential$ personalized$ therapy,$ the$ sensitivity$ of$ one$ line$ to$
alterations$in$Wnt$signaling$(278).$























accurately$ mimic$ the$ cellular$ environment$ (292,$ 293).$ Organ4on4chip$ systems$












This$ human$ iPSC4based$ cardiac$ micro4physiology$ system$ proved$ particularly$
valuable$ in$ predicting$ drug4induced$ cardiotoxicity$ (302).$ In$ addition,$ functional$
differentiation$of$human$pluripotent$stem$cells$directly$on$microfluidic$devices$has$









The$LFS$ iPSC$model$overcomes$ the$ limitations$of$current$LFS$disease$models$
such$as$those$based$on$mice,$zebrafish,$or$primary$cell$lines,$and$holds$potential$
in$ modeling$ LFS4associated$ cancers$ and$ facilitating$ preclinical$ trials.$ Precise$
genome4editing$ techniques$make$ it$ possible$ to$ expand$ the$ bank$ of$ PSCs$with$
different$p53$mutations,$which$provides$a$valuable$resource$for$precision$cancer$
medicine.$ Integration$ of$ 3D$ organoid$ and$ organs4on4chip$ systems$with$ an$ LFS$
 164$
iPSC$disease$model$offers$exciting$opportunities$for$testing$existing$both$WT$and$







WT$ p53$ or$ gain4of4function$ of$ mutant$ p53$ to$ progress$ to$ a$ fully$ malignant$




WT$ p53$ remains$ at$ relatively$ low$ intracellular$ levels$ predominantly$ due$ to$
ubiquitination$by$the$E3$ligase$MDM2$targeting$it$ for$rapid$degradation$(305).$In$
many$ cancers$ the$ MDM2$ proteins$ are$ dysregulated$ and$ exert$ an$ oncogenic$
function$ mainly$ by$ inhibiting$ p53$ tumor4suppressor$ activity$ (306).$ As$ a$ result,$
considerable$efforts$have$been$made$to$develop$compounds$that$interfere$with$the$
p53–MDM2$ interaction,$ leading$ to$ the$ discovery$ of$ nutlin43,$ RITA,$ and$MI4219$

















and$ WR41065$ (318).$ Depletion$ of$ oncogenic$ mutant$ p53$ also$ turns$ out$ to$ be$
effective.$Proper$function$of$mutant$p53$depends$on$interactions$with$the$Hsp90$






and$ the$ HSP40$ complex$ but$ also$ increases$ mutant$ p53$ degradation$ through$




Target$ Compound$ p53$ Mechanism$ Testing$Stage$ Reference$
WT$p53$
Activation$
RITA$ WT$ Inhibition$of$p53$binding$ Preclinical$ (307)$
nutlin43$ WT$ Inhibition$of$p534MDM2$interaction$ Phase$I$ (308)$



















































































related$ therapies.$ Because$ LFS$ patient4derived$ iPSCs$ would$ provide$ a$ more$
reliable$genetic$back4ground$ for$drug$efficacy$and$ toxicity$screening,$ the$ failure$
rate$of$translation$from$animal$models$to$humans$can$be$reduced.$Moreover,$LFS$
iPSCs$can$be$differentiated$into$multiple$cell$lineages,$each$of$which$can$serve$as$
a$ tumor$model.$ As$ a$ result,$ a$ p53$ drug$ screen$ can$ be$ narrowed$ down$ to$ one$
specific$tumor$type,$increasing$the$fidelity$of$the$system$and$the$expected$success$
rate.$ This$ approach$ has$ already$ shown$ promise$ for$ other$ genes.$ Engineered$
human$ embryonic$ stem$ cell$ (ESC)4derived$ neural$ progenitor$ cells$ (NPCs)$ and$
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